Cogent Biosciences, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
COGTCogent Biosciences, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Whale Activity
- Increased132
- New47
- Held39
- Decreased86
- Closed58
- No prior filing11
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 26.9M | $859.8M | increased |
| BlackRock, Inc. | 17.2M | $551.7M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.1M | $260.4M | increased |
| STATE STREET CORP | 7.8M | $248.8M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $238.5M | increased |
| Janus Henderson Group Ltd. | 7.4M | $238.0M | — |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6.0M | $190.7M | increased |
| Fairmount Funds Management LLC | 5.5M | $176.2M | held |
| WELLINGTON MANAGEMENT GROUP LLP | 4.7M | $149.8M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.5M | $143.4M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.1M | $132.4M | decreased |
| Kynam Capital Management, LP | 3.8M | $121.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Morris ArleneDirector | Sale | −3,161 | $37.54 | $119K | Aug 27, 2026 | Form 4 ↗ |
| Morris ArleneDirector | Sale | −42.3K | $37.09 | $1.6M | Aug 27, 2026 | Form 4 ↗ |
| Morris ArleneDirector | Option exercise | +3,583 | $2.52 | $9K | Aug 27, 2026 | Form 4 ↗ |
| Morris ArleneDirector | Option exercise | +41.9K | $5.64 | $236K | Aug 27, 2026 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Gift | +160.0K | $0.00 | $0 | May 19, 2026 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Gift | −160.0K | $0.00 | $0 | May 19, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Sale | −7.0M | $34.66 | $242.6M | Mar 31, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Conversion | +7.0M | — | — | Mar 31, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Sale | −3.5M | $36.40 | $127.4M | Jan 22, 2026 | Form 4 ↗ |
| Kearns EvanChief Legal Officer | Sale | −65.0K | $38.70 | $2.5M | Dec 26, 2025 | Form 4 ↗ |
| Green John L.Chief Financial Officer | Sale | −77.0K | $38.68 | $3.0M | Dec 26, 2025 | Form 4 ↗ |
| Sachs JessicaChief Medical Officer | Sale | −82.6K | $38.70 | $3.2M | Dec 26, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Sale | −90.0K | $38.74 | $3.5M | Dec 26, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Tax withholding | −140.0K | $39.45 | $5.5M | Dec 17, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Grant / award | +320.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Grant / award | +50.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Tax withholding | −367.5K | $39.45 | $14.5M | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Grant / award | +840.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Grant / award | +185.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Pinnow ColeChief Commercial Officer | Tax withholding | −94.8K | $39.45 | $3.7M | Dec 17, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $199.6M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 4.3M | $165.6M | 0.20% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.7M | $144.1M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.2M | $122.8M | 1.14% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 2.5M | $97.7M | 1.11% | Jul 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 2.4M | $91.3M | 0.13% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $75.8M | 0.08% | Jun 30, 2026 |
| Fidelity OTC Portfolio Fidelity Securities Fund | 1.9M | $72.9M | 0.17% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 1.8M | $71.4M | 3.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.8M | $70.9M | 0.21% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list COGT's shares (CUSIP 19240Q201), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- James E. FlynnSCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 8.7M shares5.1%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 13.6M shares8.0%
Jul 27, 2026 · ↗ - James E. FlynnSCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Cogent Biosciences, Inc. as the client.
Government Contracts
No federal contract awards found for Cogent Biosciences, Inc..
U.S. Patents
No USPTO patent applications found for Cogent Biosciences, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M |
| Net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | -$72.3M |
| Diluted EPS | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 |
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M |
| Cash and equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M |
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M |
| Shareholders' equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M |
As Cogent Biosciences, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗
Stock Splits
- 1-for-4Reverse splitNov 9, 2020
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 1.01Material agreementSep 2, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗

